Desmoplasia in Pancreatic Cancer. Can We Fight It?

<table class="table-group" id="tab1"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr class="thead"><td align="left">Agent</td><td align="center">Class</td></tr><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td align="left">PD 98059</td><td align="center">MEK 1 inhibitor</td></tr><tr><td align="left">U0126</td><td align="center">MEK inhibitor</td></tr><tr><td align="left">LY294002</td><td align="center">ERK inhibitor</td></tr><tr><td align="left">PP1-PP2</td><td align="center">T<i>β</i>R inhibitors</td></tr><tr><td align="left">SB431542 and SB525334</td><td align="center">T<i>β</i>RI selective inhibitor</td></tr><tr><td align="left">LY2109761</td><td align="center">T<i>β</i>RI/II dual inhibitor</td></tr><tr><td align="left">SD-208</td><td align="center">T<i>β</i>RI inhibitor</td></tr><tr><td align="left">AP 12009 </td><td align="center">TGF<i>β</i>2 mRNA phosphorothioate antisense oligodeoxynucleotide </td></tr><tr><td align="left">2G8</td><td align="center">Neutralising antibody to T<i>β</i>R2 neutralising antibody</td></tr><tr><td align="left">IPI-926</td><td align="center">SMO Semisynthetic cyclopamine analogue inhibitor</td></tr><tr><td align="left">GDC-0449</td><td align="center">2-arylpyridine class SMO inhibitor</td></tr><tr><td align="left">iRGD</td><td align="center">Disulfide-based cyclic RGD tumour-penetrating peptide</td></tr><tr><td align="left">CP870,893</td><td align="center">IgG2 antibody to CD40</td></tr><tr><td align="left">AB0023</td><td align="center">Allosteric inhibitor of LOX-L2</td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

Classification of antidesmoplastic agents.

Gastroenterology Research and Practice

tab1

Table 1

Table 1: Desmoplasia in Pancreatic Cancer. Can We Fight It? 